Reports
Reports
Sale
The global market value in 2023 was USD 9.41 billion, driven by the increasing prevalence of the disease and the introduction of new therapies across the globe. The global cystic fibrosis market size is anticipated to grow at a CAGR of 13.4% during the forecast period of 2024-2032 to achieve a value of USD 29.19 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Cystic fibrosis (CF) is an inherited disease that causes severe damage to the lungs, digestive system, and other body organs. Cystic fibrosis affects the cells responsible for the production of mucus, sweat, and digestive juices. Normally, these secreted fluids are thin and slippery, however, in people with cystic fibrosis, a faulty gene causes the secretions to become sticky and thick. These secretions, rather than acting as lubricants, clog tubes, ducts, and passageways, particularly in the lungs and pancreas.
Despite the fact that cystic fibrosis is a progressive disease that necessitates daily care, people with CF are usually able to do all the daily activities. Patients suffering from CF now have a better quality of life than previous generations of CF patients. Due to the advancements in screening and treatment, people with CF can now live in their mid- to late-30s or 40s, with some even living into their 50s.
The signs and symptoms in the respiratory and digestive systems include:
The thick mucus can also obstruct the tubes that transport digestive enzymes from the pancreas to the small intestine. Without these digestive enzymes, the intestines are unable to absorb all of the nutrients in the food consumed. It often results in:
CF is caused by a mutation in the "cystic fibrosis transmembrane conductance regulator" gene, or CFTR gene. Gene regulates the movement of water and salt into and out of the cells. A sudden mutation or change in the CFTR gene causes the mucus to thicken and stickier than usual. This abnormal mucus raises the salt content of the sweat and accumulates in various organs throughout the body, including the intestines, pancreas, liver, and lungs.
According to the cystic fibrosis treatment market research report, the market can be categorized into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Treatment Method
Market Breakup by Drug Class
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
According to the Cystic Fibrosis Foundation, over 30,000 people in the United States have cystic fibrosis, and an additional 1,000 are diagnosed each year. Since CF is a progressive disease, it worsens over time and thus the treatment is extremely crucial.
Although there is no cure for CF, there are several treatments that can help relieve the symptoms and reduce the risk of complications. The available treatments include antibiotics, mucus-thinning medication, NSAIDs, Bronchodilators, CFTR, whereas the surgical procedures include bowel surgery, feeding tube, and double lung transplant. Other than medications and surgical treatment, chest physical therapy and home care are also included in the management of this disease.
The market growth has been aided by an increase in the number of cystic fibrosis patients worldwide. Cystic fibrosis pharmacotherapy has resulted in a number of advancements in the treatment of this ailment, which is positively impacting the market growth.
Cystic fibrosis treatment market growth is expected to be driven by the rise in non-profit initiatives, increase in government-backed legislation, and increases in research and development funding. Researchers are expected to increase their investment in research and development activities in order to fuel market growth. There are a number of drugs in development, including Symdeko, VX-561, ELX-02, and ABBV-3067.
In terms of region, the global market is expected to be dominated by North America. The dominance can be attributed to the rapid increase in cystic fibrosis cases in the region, an increase in patients with various respiratory diseases affecting cystic fibrosis, and higher healthcare costs.
Europe is in the second position, following North America in terms of demand for advanced drugs due to the prevalence of the disease and the increased use of advanced drugs to achieve better results.
On the other hand, there are some factors which have been restricting the growth of the market. Along with the positive effects these medicines provide, there are some side effects that come with these medicines. These undesirable side effects include upper respiratory tract infections, liver problems, chest pain, and an increase in blood pressure, among other issues, and may obstruct the growth of the treatment market.
In the past few years, it has been observed that patients with cystic fibrosis have been able to live longer due to the rapid improvements in clinical care. There are some European countries where life expectancy has increased to 30-40 years.
The growth of the cystic fibrosis treatment market is driven by the treatment of lung diseases and improved nutrition. The current treatment strategies can be improved by identifying new effective agents. Various clinical trials are underway for several drugs that are suspected of being effective in combating CFTR dysfunction. Cystic fibrosis is a condition that affects many organs.
The development of drugs to treat lung disease, dyspepsia, and pancreatic malabsorption has become increasingly important. Researchers are developing drugs in many fields, including anti-inflammatory treatments, ion channel blockers, and genetic therapies.
A major objective of pancreatic insufficiency treatment is to develop pancreatic enzymes that work most efficiently. A variety of treatments for cystic fibrosis are driving the growth of the cystic fibrosis treatment market.
The cystic fibrosis treatment market is experiencing rapid growth due to an increasing demand for research.
The report gives an in-depth analysis of the key players involved in the global cystic fibrosis treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Treatment Methods |
|
Breakup by Drug Class |
|
Breakup by Drug Molecule Type |
|
Breakup by Route of Administration |
|
Breakup by Treatment Channel |
|
Breakup by Distribution Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
Cystic Fibrosis Treatment Market Size
Cystic Fibrosis Treatment Market Growth
Cystic Fibrosis Treatment Companies
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Cystic Fibrosis Disease Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Cystic Fibrosis Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Cystic Fibrosis Epidemiology (2016-2031)
5.3 Europe Cystic Fibrosis Epidemiology (2016-2031)
5.4 Asia-Pacific Cystic Fibrosis Epidemiology (2016-2031)
5.5 Latin America Cystic Fibrosis Epidemiology (2016-2031)
5.6 Middle East & Africa Cystic Fibrosis Epidemiology (2016-2031)
6 Global Cystic Fibrosis Market Overview
6.1 Global Cystic Fibrosis Market Historical Value (2017-2023)
6.2 Global Cystic Fibrosis Market Forecast Value (2024-2032)
7 Global Cystic Fibrosis Market Landscape
7.1 Cystic Fibrosis: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Cystic Fibrosis: Product Landscape
7.2.1 Analysis by Treatment Methods
7.2.2 Analysis by Drug Class
7.2.3 Analysis by Molecule Type
7.2.4 Analysis by Route of Administration
7.2.5 Analysis by Distribution Channel
8 Cystic Fibrosis Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Cystic Fibrosis Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Cystic Fibrosis Market Segmentation
11.1 Global Cystic Fibrosis Market by Treatment Methods
11.1.1 Market Overview
11.1.2 Medications
11.1.3 Devices
11.2 Global Cystic Fibrosis Market by Drug Class
11.2.1 Market Overview
11.2.2 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
11.2.3 Bronchodilators
11.2.4 Mucolytic
11.2.5 Pancreatic Enzyme Supplement
11.2.6 Others
11.3 Global Cystic Fibrosis Market by Drug Molecule Type
11.3.1 Market Overview
11.3.2 Small Molecules
11.3.3 Biologics
11.4 Global Cystic Fibrosis Market by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Parentals
11.4.4 Others
11.5 Global Cystic Fibrosis Market by Treatment Channel
11.5.1 Market Overview
11.5.2 Public
11.5.3 Private
11.6 Global Cystic Fibrosis Market by Distribution Channel
11.6.1 Market Overview
11.6.2 Hospital Pharmacy
11.6.3 Retail Pharmacy
11.6.4 Online Pharmacy
11.6.5 Others
11.7 Global Cystic Fibrosis Market by Region
11.7.1 Market Overview
11.7.2 North America
11.7.3 Europe
11.7.4 Asia Pacific
11.7.5 Latin America
11.7.6 Middle East and Africa
12 North America Cystic Fibrosis Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Cystic Fibrosis Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Cystic Fibrosis Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Cystic Fibrosis Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Cystic Fibrosis Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 AbbVie Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Allergan
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Chiesi Farmaceutici SpA
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 F. Hoffmann-La Roche Ltd.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Gilead Sciences
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Novartis AG
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Pharmaxis Ltd.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 PTC Therapeutics
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Vertex Pharmaceuticals
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Demegen, Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Mor Research Applications
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Alaxia
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Alcresta Therapeutics, Inc.
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
23.14 AstraZeneca
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.14.5 Certifications
23.15 Genentech, Inc.
23.15.1 Financial Analysis
23.15.2 Product Portfolio
23.15.3 Demographic Reach and Achievements
23.15.4 Mergers and Acquisitions
23.15.5 Certifications
23.16 Pfizer Inc.
23.16.1 Financial Analysis
23.16.2 Product Portfolio
23.16.3 Demographic Reach and Achievements
23.16.4 Mergers and Acquisitions
23.16.5 Certifications
23.17 Mylan N.V.
23.17.1 Financial Analysis
23.17.2 Product Portfolio
23.17.3 Demographic Reach and Achievements
23.17.4 Mergers and Acquisitions
23.17.5 Certifications
23.18 Alcresta Therapeutics, Inc.
23.18.1 Financial Analysis
23.18.2 Product Portfolio
23.18.3 Demographic Reach and Achievements
23.18.4 Mergers and Acquisitions
23.18.5 Certifications
23.19 Teva Pharmaceutical Industries Ltd
23.19.1 Financial Analysis
23.19.2 Product Portfolio
23.19.3 Demographic Reach and Achievements
23.19.4 Mergers and Acquisitions
23.19.5 Certifications
23.20 Bayer AG
23.20.1 Financial Analysis
23.20.2 Product Portfolio
23.20.3 Demographic Reach and Achievements
23.20.4 Mergers and Acquisitions
23.20.5 Certifications
24 Cystic Fibrosis Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Globally, Cystic Fibrosis market reached a value of USD 9.41 billion in 2023.
The market is projected to expand at a CAGR of 13.4% from 2024 to 2032, growing to USD 29.19 billion by 2032.
The major regions in the industry are North America, Latin America, the Middle East, Africa, Europe, and the Asia Pacific, with North America accounting for the largest share of the market.
Factors predicted to expand the market size include the rising prevalence of genetic disorders worldwide which will expand the market of cystic fibrosis treatment.
Hospital is the end-user that is dominating the global market.
The key players in the market include Genentech, Inc., Gilead Sciences, Inc., Novartis International AG, Vertex Pharmaceuticals Incorporated, Johnson & Johnson Services, Inc, Allergan Plc., Nestle Health Science S.A., AbbVie Inc., Horizon Therapeutics Plc., Chiesi Farmaceutici S.P.A., Pharmaxis Ltd., and Teva Pharmaceuticals Industries Ltd , among others.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.